Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage III or IV adenocarcinoma of the prostate not potentially curable by surgery or radiotherapy~* Measurable tumors or tumor markers~* No response to antiandrogen withdrawal~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT no greater than 2 times normal~* No hepatic failure~Renal:~* BUN less than 60 mg/dL~* Creatinine no greater than 2.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~* Blood ammonia normal~* No chronic renal failure~Cardiovascular:~* No severe heart disease~Pulmonary:~* No severe lung disease~Other:~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infection or fever~* No other concurrent serious disease~* No other prior or concurrent malignancy within the past 2 years~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* At least 4 weeks since prior hormonal therapy and recovered~* Prior corticosteroids for at least 2 months allowed, but must be on stable or decreasing dose during study participation~Radiotherapy:~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy and recovered~Surgery:~* See Disease Characteristics~* At least 4 weeks since prior surgery and recovered~Other:~* At least 4 weeks since prior experimental clinical trial~* No other concurrent therapy for metastatic disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).